Research · Source update
Retatrutide TRIUMPH-2 reports results in type 2 diabetes
Source context: Read the linked original research or registry entry for study status and limitations.
Eli Lilly reported results for retatrutide in adults with obesity or overweight and type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Eli Lilly reported results for retatrutide in adults with obesity or overweight and type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly TRIUMPH-2 and TRIUMPH-3 results, dated 2026-07-23.
What did the source report?
At 80 weeks the company reported up to 20.8% average weight loss and HbA1c improvements up to 1.6 percentage points. The sponsor reported dose-group mean weight loss of 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg respectively, compared with 4.0% for placebo over 80 weeks.
How should the results be interpreted?
People with diabetes may respond differently from those without; this was not a direct comparison with marketed alternatives. HbA1c reduction was also measured: improvement in glucose control and weight loss are related but distinct endpoints.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
The population and endpoint matter when comparing weight-loss numbers. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
The population and endpoint matter when comparing weight-loss numbers.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-07-23. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly TRIUMPH-2 and TRIUMPH-3 results ↗
Source event or update: 2026-07-23. Our interpretation is educational and does not replace medical or insurance advice.